Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.

ABSTRACT:

Introduction

Long-acting β₂-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are established maintenance bronchodilator treatments for chronic obstructive pulmonary disease (COPD) with the potential to increase heart rate (HR) and impact blood pressure (BP). While previous studies indicate that HR and BP are not negatively influenced by tiotropium or olodaterol monotherapy, the effect of tiotropium/olodaterol has not been evaluated. We report a post hoc analysis of the effect of dual bronchodilation with tiotropium/olodaterol versus monocomponents on HR and BP in patients with moderate-to-very-severe COPD included in the large TONADO^® study.

Methods

The TONADO^® trials (1237.5 [NCT01431274] and 1237.6 [NCT01431287]) were two rep

SUBMITTER: Andreas S 

PROVIDER: S-EPMC7428407 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature